- What we do
- Who we are
CVML advised AB Science on a EUR 12.0 million private placement of new shares with subscription warrants attached.
The securities were subscribed by funds managed by RA Capital Management, a US based healthcare focused asset manager.
The private placement was managed by Chardan Capital Markets as Bookrunner and Lead Placement Agent.
The CVML team included Paris-based partners Pierre Treille and Thierry Cotty and associate Elise Pouron.
Founded in 2001 and listed on Euronext since 2010, AB Science is a pharmaceutical company specialized in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells.